GlassScriptPhysician profile
Luis J Barba
NPI 1992178750
$4,285.14
in general payments reported to CMS, 2019-2025
26 companies · $440 in 2025
The $440 reported for 2025 was more than what 82% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $950 · 2021: $569 · 2022: $435 · 2023: $543 · 2024: $628 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $942.35 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $574.79 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $518.52 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.49 | 2019-2025 | Jardiance |
| Pfizer INC. | $306.82 | 2019-2024 | |
| Lilly USA, LLC | $267.26 | 2019-2024 | Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $236.13 | 2019-2024 | |
| Amgen INC. | $193.67 | 2019-2023 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $159.85 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.00 | 2021-2024 | |
| Novo Nordisk INC | $88.27 | 2022-2025 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $83.87 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $68.02 | 2024 | Nuzyra |
| Esperion Therapeutics, INC. | $61.76 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $58.52 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $54.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.08 | 2019-2022 | |
| Philips North America LLC | $24.10 | 2025 | Vest Therapy Und |
| Photonicare INC | $21.53 | 2025 | Otosight Middle Ear Scope |
| Abbott Laboratories | $21.49 | 2024 | Eterna |
| Biohaven Pharmaceuticals, INC. | $18.27 | 2021 | |
| Exact Sciences Corporation | $18.25 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $16.25 | 2025 | Voquezna |
| Medtronic Vascular, INC. | $15.99 | 2020 | |
| Gilead Sciences, INC. | $15.84 | 2020 | |
| Medtronic, INC. | $15.26 | 2023 | Minimed 770g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Barba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.